好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Comprehensive Analysis of Migraine Burden and Treatment Trends: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases.
Headache
P9 - Poster Session 9 (8:00 AM-9:00 AM)
12-005
Migraine affects about 14.4% of the population causing substantial burden. Our  objective was to describe the populations of individuals diagnosed with migraine headache with regards to diagnosis and review healthcare service utilization across various categories.
.
We reviewed recent (8/2018 - 7/2021) medical and pharmacy data from Health Verity for N=187,780. The final sample included 76,684 migraine cases matched to (matching criteria included demographic, geographic, comorbidity, and time-based variables) 76,684 non-migraine controls.

Within the migraine group, 68.4% were female (44.7 yrs, SD=13.9) vs. 69.7% female in the control group (45.6 yrs, SD=14.6).  At baseline, migraine cases had higher rates of all-cause healthcare service utilization in each utilization subgroup: Migraine group was more likely to be hospitalized (10.4% vs. 4.5%*), have an Emergency Department (ED) visit (30.3% vs. 11.9%*), have a primary care physician visit (88.1% vs. 54.4%*), have a neurology visit (20.3% vs. 2.0%*), have higher overall use of other medical services, and have higher prescription fill rates  (21.3 fills vs 9.53*) (*= p < 0.05).

Similar differences were noted during the follow-up period, with migraine cases having higher rates of all-cause healthcare service utilization in each utilization subgroup. Notably, Neurology visits were 12.2 times more likely among the migraine case group compared to the control group, followed by other outpatient visits (OR: 9.5*), prescription fills (OR: 8.8*), PCP visits (OR: 6.9*), inpatient hospitalizations (OR: 3.4*), and ED visits (OR: 2.9*).


Migraine groups experienced significantly higher rates of healthcare service utilization across various categories, including hospitalization, ED and PCP visits, neurology consultations, and prescription fill rates underscoring continuous need to enhance the management of this condition.
Authors/Disclosures
Mariya Petrova (Click Therapeutics)
PRESENTER 		Mariya Petrova has received personal compensation for serving as an employee of Click Therapeutics. Mariya Petrova has received research support from NIH.
Olya Besedina (Click Therapeutics Inc.) Miss Besedina has nothing to disclose.
Brendan Hare No disclosure on file
Alankar Gupta, MD (Click Therapeutics) Dr. Gupta has nothing to disclose.
Shaheen E. Lakhan, MD, PhD, MEd, FAAN Dr. Lakhan has received personal compensation for serving as an employee of Zogenix, Fern Health, Thriveworks, The Learning Corp, TriNet, Click Therapeutics. Dr. Lakhan has received personal compensation in the range of $1,000,000+ for serving as a Consultant for Shaheen Lakhan, MD, PhD, LLC. Dr. Lakhan has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurocrine, Fern Health, Lin Health. Dr. Lakhan has received personal compensation in the range of $500,000-$999,999 for serving as an officer or member of the Board of Directors for Click Therapeutics, SpineThera. Dr. Lakhan has stock in Zogenix, NeuroSport, Click Therapeutics, SpineThera.